Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Edesa Biotech, Inc. EDSA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
66/100
3/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Edesa Biotech, Inc. (EDSA) is a Biotechnology company in the Healthcare sector, currently trading at $5.22. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Valuation: EDSA trades at a trailing Price-to-Earnings (P/E) of -6.2 (S&P 500 average ~25).

Net income is $7M (loss), growing at +20.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $12M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 10.67 (strong liquidity). Debt-to-assets is 0%. Total assets: $14M.

Analyst outlook: 2 / 2 analysts rate EDSA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

EDSA SharesGrow Score Overview

82/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EDSA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
EDSA: +0%/yr revenue is, +20.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet EDSA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 10.67 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
EDSA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate EDSA as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.72-9.37
Volume418.45K
Avg Volume (30D)4.46M
Market Cap$43.58M
Beta (1Y)-0.68
Share Statistics
EPS (TTM)-1.27
Shares Outstanding$5.68M
IPO Date2010-06-21
Employees16
CEOPardeep Nijhawan
Financial Highlights & Ratios
Gross Profit$-119.27K
EBITDA$-7.07M
Net Income$-7.19M
Operating Income$-7.91M
Total Cash$10.79M
Net Debt$-10.79M
Total Assets$13.53M
Price / Earnings (P/E)-4.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINCA27966L3065

Price Chart

Track all markets on TradingView
EDSA
Edesa Biotech, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.72 52WK RANGE 9.37

People Also View

PALI
PALI
Palisade Bio, Inc.
$2.06
+3.52%
 THRD
THRD
Third Harmonic Bio, Inc.
$5.38
-0.09%
 NTRB
NTRB
Nutriband Inc.
$4.06
+2.01%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
 RNXT
RNXT
RenovoRx, Inc.
$1.03
+0.98%
 CING
CING
Cingulate Inc.
$5.35
-2.73%
 LGVN
LGVN
Longeveron Inc.
$1.12
-0.89%
 SNTI
SNTI
Senti Biosciences, Inc.
$0.93
+2.98%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message